ESTRELLA IMMUNOPHARMA, INC. Proceeds from Issuance of Private Placement
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Proceeds from Issuance of Private Placement of $1.35 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2025-08-12
- ESTRELLA IMMUNOPHARMA, INC. proceeds from issuance of private placement for the quarter ending 2021-12-31 was $0.00.
- ESTRELLA IMMUNOPHARMA, INC. proceeds from issuance of private placement for fiscal 2021 was $3.12M.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2025-06-30 | $1.35M 10-Q · filed 2025-08-12 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $3.12M 10-K · filed 2023-03-14 | ||
| 2021-09-30 | $3.12M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |